文献支持
Spike S1 RBD (B.1.1.7, Alpha V
ariant) (N501Y) (SARS-CoV-2): ACE2 Inhibitor Screening Chemiluminescence Assay Kit- 询价
- BPS Bioscience
- 美国
- 78140
- 2025年07月15日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
-80°C
- 保质期：
This assay kit will perform optimally for up to 6 months from date of receipt when the materials are stored as directed.
- 英文名：
Spike S1 RBD (B.1.1.7, Alpha Variant) (N501Y) (SARS-CoV-2): ACE2 Inhibitor Screening Chemiluminescence Assay Kit
- 库存：
1
- 供应商：
BPS Bioscience Inc.
- 规格：
盒
The Spike RBD (SARS-CoV-2) UK variant (N501Y):ACE2 Inhibitor Screening Chemiluminescence Assay Kit is designed for screening and profiling inhibitors of the interaction of ACE2 with the UK variant (N501Y) of the SARS-CoV-2 Spike RBD protein. The key to this kit is the high sensitivity of detection of ACE2-Biotin protein by Streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, Spike RBD protein UK variant is coated on a 96-well transparent plate. Next, ACE2-Biotin is incubated with Spike RBD UK variant on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a luminometer or microplate reader capable of reading chemiluminescence.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
1. Wang P. et al., Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. bioRxiv 2021 Jan 26; 2021.01.25.428137
2. Shen X., et al., SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. bioRxiv. 2021 Jan 29; 2021.01.27.428516
3. Hoffman M. et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181:1-10
2. Shen X., et al., SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. bioRxiv. 2021 Jan 29; 2021.01.27.428516
3. Hoffman M. et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181:1-10
技术资料暂无技术资料 索取技术资料
文献支持
Spike S1 RBD (B.1.1.7, Alpha Variant) (N501Y) (SARS-CoV-2): ACE2 Inhibitor Screening Chemiluminescence Assay Kit
询价
